TheStreet) -- Adam Feuerstein's take on the biotech week that was Oct. 11, 2010:
(KG) for $3.6 billion to bolster its pain drug franchise.
Pfizer adds new partners through King Buy
(ALKS) CEO Richard Pops (@popsalks)
breaks company news on Twitter. Bravo! (via @MikeHuckman)
The news broken by Pops: Finally, a drug approval in October! Alkermes received FDA clearance to market
Vivitrol as a treatment for opioid addiction
not as lucky:
FDA denies approval to both of their drugs
receives belated FDA approval for Acthar as a treatment for infantile spasms.
The week's top-performing sector stocks:
Molecular Insight Pharmaceuticals
Johnson & Johnson's
abiraterone boosts survival by four months
for patients with advanced prostate cancer.
reported a second clinical trial win for the lymphoma drug brentuximab vedotin.
Biotech Stock Mailbag
Matt Herper on the
fight against drug-resistant germs
Cancer drug analyst and blogger Sally Church
spends the week at the European cancer conference known as ESMO
The week's worst-performing sector stocks:
reports third quarter Cubicin sales of $154 million, lower than the consensus estimate of $162 million. The company reports higher-than-expected earnings for the quarter on lower operating expenses.
The biggest (sore) losers:
Chemist and blogger Derek Lowe takes another
skeptical look at the anti-aging claims
made about GlaxoSmithKline's resveratrol.
Will the withdrawal of Meridia
help or hurt other weight-loss pills
? (via Pharmalot)
editor Ivan Oransky on
first-ever stem cell study in patients with spinal cord injury
"Scrapers" are scouring web sites
looking for patients' personal information
reports weaker-than-expected sales of its three most important drugs -- Avastin, Rituxan and Herceptin. Overall, third quarter revenue fell 7%.
strike a licensing deal to develop cancer drugs based on ImmunoGen's "armed antibody" drug delivery technology.
licenses two experimental cancer drugs to
Perfect FDA Drug Approval Pickers
cut 25% of its workforce in a restructuring move.
The week in financings:
($19 million) and
FDA doesn't always heed the
recommendations offered by its advisory panels
. (via @matthewherper)
Phase III data on
implantable addiction drug is published in JAMA
drops development of a drug for the controversial disorder known as female sexual dysfunction
completes acquisition of
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: